Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Q-linea AB ( (SE:QLINEA) ) has shared an announcement.
Q-linea has signed its first distribution agreement in South Asia with Genetic Trading, a leading Bangladeshi distributor, in a move that advances the company’s global expansion strategy. Genetic Trading is completing product registration in Bangladesh, after which the first ASTar instrument order will be deployed for evaluation at a major hospital, positioning Q-linea to address the region’s significant sepsis and antimicrobial resistance challenges and laying the groundwork for broader South Asian market entry targeted for 2026.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB is a Swedish medical technology company specializing in rapid antimicrobial susceptibility testing (AST) for bloodstream infections and sepsis. Its flagship system, ASTar, is used by hospitals to significantly shorten the time to optimal antimicrobial therapy, supporting more effective treatment decisions and contributing to sustainable healthcare and antibiotic stewardship. The company is headquartered in Uppsala with regional offices in Italy and the United States, and its ASTar instrument and consumables are both CE-IVD marked and FDA 510(k) cleared.
Average Trading Volume: 11,295
Technical Sentiment Signal: Sell
Current Market Cap: SEK416.4M
Learn more about QLINEA stock on TipRanks’ Stock Analysis page.